AmerisourceBergen Corp. (ABC) Insider Robert P. Mauch Sells 1,000 Shares
AmerisourceBergen Corp. (NYSE:ABC) insider Robert P. Mauch sold 1,000 shares of AmerisourceBergen stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $97.94, for a total transaction of $97,940.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of AmerisourceBergen Corp. (ABC) opened at $93.96 on Friday. The stock has a market capitalization of $20,495.12, a P/E ratio of 20.25, a price-to-earnings-growth ratio of 1.39 and a beta of 1.03. The company has a debt-to-equity ratio of 1.61, a current ratio of 0.95 and a quick ratio of 0.50. AmerisourceBergen Corp. has a 12-month low of $71.90 and a 12-month high of $106.27.
AmerisourceBergen (NYSE:ABC) last announced its earnings results on Tuesday, February 6th. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.20. The company had revenue of $40.47 billion for the quarter, compared to analyst estimates of $40.42 billion. AmerisourceBergen had a return on equity of 53.65% and a net margin of 0.66%. The firm’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.36 earnings per share. equities research analysts expect that AmerisourceBergen Corp. will post 6.58 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Hikari Tsushin Inc. purchased a new stake in shares of AmerisourceBergen during the fourth quarter worth $106,000. Delpha Capital Management LLC purchased a new stake in shares of AmerisourceBergen during the fourth quarter worth $137,000. Vantage Investment Advisors LLC purchased a new stake in shares of AmerisourceBergen during the fourth quarter worth $156,000. TRUE Private Wealth Advisors purchased a new stake in shares of AmerisourceBergen during the fourth quarter worth $203,000. Finally, Zeke Capital Advisors LLC purchased a new stake in shares of AmerisourceBergen during the third quarter worth $210,000. 65.98% of the stock is currently owned by institutional investors.
ABC has been the topic of several analyst reports. Zacks Investment Research raised shares of AmerisourceBergen from a “hold” rating to a “buy” rating and set a $103.00 price target on the stock in a research report on Thursday, February 8th. Goldman Sachs Group raised shares of AmerisourceBergen from a “neutral” rating to a “buy” rating in a research report on Friday, December 15th. Deutsche Bank initiated coverage on shares of AmerisourceBergen in a research report on Monday, December 4th. They set a “buy” rating and a $97.00 price target on the stock. Leerink Swann set a $105.00 price target on shares of AmerisourceBergen and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Finally, Cowen set a $107.00 price target on shares of AmerisourceBergen and gave the company a “buy” rating in a research report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $102.46.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.